Imricor Advances Towards Regulatory Approval in US and Europe for MRI-Guided Cardiac Ablation Technology
核心洞察
Imricor's FDA premarket approval review for its initial module was successfully completed ahead of schedule, marking a significant step toward US approval.
In Europe, the Vision-MR Ablation Catheter 2.0 (搜索) is awaiting final certification after a positive audit, aligning with the stringent Medical Device Regulations (MDR).
Imricor's technology offers improved visualization and outcomes in cardiac ablations, potentially reducing the need for repeat procedures compared to traditional X-ray fluoroscopy.
Imricor Medical Systems (搜索) is making strides in securing regulatory approvals in both the United States and Europe for its innovative MRI-compatible cardiac ablation devices. The company's technology aims to improve the treatment of arrhythmias (搜索) by providing clearer imaging and potentially better outcomes compared to traditional X-ray fluoroscopy.
FDA Review Completed Ahead of Schedule
Imricor announced that the U.S. Food and Drug Administration (FDA) completed the review of its first premarket approval (PMA) module ahead of schedule. The submission included data pertaining to the Vision-MR ablation catheter 2.0 (搜索) and RF-5000 ablation generator (搜索), irrigation pump, tubing set, and remote control unit. The module encompassed preclinical animal study data, biocompatibility assessments, and sterilization validation.
European Regulatory Milestones
In Europe, Imricor's Notified Body, TÜV SÜD, conducted an on-site audit of Imricor’s facilities with positive results. The audit focused on adherence to the Medical Device Directive (MDD) and Medical Device Regulation (MDR), as well as MDR review for the design controls and manufacturing of the Vision-MR Ablation Catheter 2.0 (搜索) and Advantage-MR EP Recorder/Stimulatory System. The company is expected to receive certification to manufacture these products under the new MDR regime.
The MDR technical review of the Vision-MR Ablation Catheter 2.0 (搜索) has been successfully completed, with only final certification pending before manufacturing and sales can commence. The commercial launch of the new MDR Advantage-MR system is anticipated in Q1 2025, ahead of Imricor’s initial projections.
Improving Arrhythmia Treatment with MRI-Guided Ablation
Imricor's MRI-compatible devices are designed for cardiac ablations, a procedure used to treat arrhythmias (搜索) by targeting and destroying heart cells causing irregular heartbeats. Current ablation techniques rely on X-ray fluoroscopy, which struggles to visualize soft tissues like the heart, leading to lower long-term success rates (often below 50%) and the need for repeat procedures. Imricor's technology offers clearer imaging, potentially improving outcomes and reducing radiation exposure for both patients and staff.
Clinical Trials Underway
Imricor is currently conducting the Vision-MR Ablation of Atrial Flutter (搜索) (VISABL-AFL) pivotal clinical trial to support FDA approval of its products, with the aim of achieving approval in 2025. In Europe, the company is preparing to initiate the VISABL-VT clinical trial for ventricular tachycardia (搜索) (VT), its second indication.
Leadership Perspective
"The FDA review process for our first module went very smoothly and in a timeframe that exceeded our own expectations," said Steve Wedan, Chair and CEO of Imricor. He also noted the progress in navigating the approval process for the Vision-MR Ablation Catheter 2.0 (搜索) under the new MDR regime, stating, "Importantly, the 2.0 catheter is the one used in the VISABL-VT and VISABL-AFL trials, so everything is coming together nicely worldwide."